RxDoctor Payments Data

Hazar Michael, MD

Gastroenterology · Berkeley Heights, NJNPI 1144392242

Payments from drug & device makers

$755in general payments, 2019–2025

Across 28 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$258
  • Gilead$189
  • Bristol Myers Squibb$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$65
  • Olympus America Inc.$36
  • Ferring Pharmaceuticals Inc.$33
  • plus $102 from 4 others

What the payments were for

  • Food & beverage$73597%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$755 in reported general payments places this provider in the 25th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$212,144
Medicare patients
590
Services billed
2,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase33$162,724
ZenpepLipase/Protease/Amylase12$35,294
LinzessLinaclotide24$30,433
Famotidine299$7,044
Mesalamine19$6,881
Pantoprazole Sodium295$5,053
Ursodiol22$4,420
Lansoprazole20$3,716
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates44$3,000
Omeprazole197$2,733
Esomeprazole Magnesium62$2,244
CholestyramineCholestyramine (With Sugar)15$2,106
Colestipol Hcl13$1,540
Rabeprazole Sodium16$1,330
Mercaptopurine15$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$258$193,15757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Berkeley Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →